Aethlon Medical, Inc.'s Chairman Interviewed on WallStreetReporter.com.

Business Editors & Health/Medical Writers

SAN DIEGO--(BW HealthWire)--Jan. 10, 2001

Aethlon Medical, Inc., (OTCBB: AEMD - news) Chairman James Joyce conducted an audio interview with WallStreetReporter.com, the premier information source for professional investors seeking new investment ideas and information on news-making companies.

During the interview, Mr. Joyce discussed one of the company's lead developmental products, the HIV Hemopurifier, which is designed to reduce the burden of the HIV virus on the body, thereby enhancing the effectiveness of established HIV drugs and to treat patients who have become resistant to conventional therapies.

The interview with Mr. Joyce can be accessed at http://www.wallstreetreporter.com. It is currently available on audio. In order to hear this exclusive audio interview, your computer must be appropriately configured.

About Aethlon Medical

Aethlon Medical is applying its proprietary platform technology known as the Hemopurifier(TM) to develop an extracorporeal therapeutic treatment for AIDS. Recent pre-clinical trials have documented the rapid removal of up to 70% of the circulating HIV virus during one sixty-minute application. Products already developed from the Hemopurifier platform are designed to treat Lead Poisoning, Iron Overload, and curb the side effects of cisplatin based Chemotherapy. The Hemopurifier is scheduled to be presented to the science community at the Cambridge Healthtech Institute's Seventh Annual Blood Product Safety Conference on Tuesday, February 6, 2001, in Washington, DC.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. (the "Company"), or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Readers of this press release may obtain additional information on the Company in reports and other information filed in accordance with the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such reports and other information filed by the Company can be inspected and copied at the public reference facilities maintained by the Commission at the Public Reference Room, 450 Fifth Street, N.W., Washington, DC 20549. Copies of such material can also be obtained at prescribed rates from the Public Reference Section of the Commission, Washington, DC 20549 or by calling the Commission at 1-800-SEC-0330. In addition, Registration Statements and other filings made with the Commission through its Electronic Data Gathering Analysis and Retrieval System ("EDGAR") and publicly available through the Commission's website located at http://www.sec.gov.